Open AccessDoes nitric oxide inhalation need to be reassessed?
Author(s) -
Khalid A Dahiyat
Publication year - 2016
Publication title -
annals of king edward medical university
Language(s) - English
Resource type - Journals
eISSN - 2079-7192
pISSN - 2079-0694
DOI - 10.21649/akemu.v12i1.822
Subject(s) - medicine , cinahl , intensive care medicine , medline , drug approval , nitric oxide , drug , pharmacology , psychiatry , political science , psychological intervention , law
Background: Inhaled nitric oxide is a drug which has been given FDA approval in 1999 but was not found prior to approval to be safe for use in premature neonates. Aim: To review and assess the studies which was done prior to its approval in order to find out what evidences the approval by the FDA was based on. Methods: A thorough search of the electronic data-base, Medline, Embase, Cinahl, Google. Conclusion: The use of this drug in treatment of the Pulmonary hypertension in premature babies is still contraversial and hold a serious untoward effects on the health, it should only used as the last ditch.